Management and Prevention of Herpes Zoster in the Immunocompromised Inflammatory Bowel Disease Patient: A Clinical Quandary

Inflammatory Bowel Diseases

Volumn 22, Issue 10, 2016, Pages 2538-2547

  Côté Daigneault, Justin ^a,b   Peerani, Farhad ^a,c   Macmahon, Eithne ^d   Delaporte, Emmanuel ^e   Rahier, Jean François ^f   Colombel, Jean Frédéric ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^e UNIV LILLE   (France)

^f UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

Author keywords

herpes zoster; inflammatory bowel disease; opportunistic infection; shingles; varicella zoster virus

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; VARICELLA ZOSTER VACCINE;

CLINICAL FEATURE; HERPES ZOSTER; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; INFLAMMATORY BOWEL DISEASE; PHARMACEUTICAL CARE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VACCINATION; ADULT; CHEMICALLY INDUCED; DRUG CONTRAINDICATION; FEMALE; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTION; VIROLOGY;

ADULT; CONTRAINDICATIONS, DRUG; FEMALE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS;

EID: 84988569079     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000902     Document Type: Review

References (49)

1. Cohen JI. Clinical practice: herpes zoster. N Engl J Med. 2013;369:255-263
2. Leung J, Harpaz R, Molinari NA, et al. Herpes zoster incidence among insured persons in the United States, 1993-2006: evaluation of impact of varicella vaccination. Clin Infect Dis. 2011;52:332-340
3. Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007;44(suppl 1):S1-S26
4. Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:1483-1490
5. Marehbian J, Arrighi HM, Hass S, et al. Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. Am J Gastroenterol. 2009;104:2524-2533
6. Long MD, Martin C, Sandler RS, et al. Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37:420-429
7. Chen SY, Suaya JA, Li Q, et al. Incidence of herpes zoster in patients with altered immune function. Infection. 2014;42:325-334
8. Cullen G, Baden RP, Cheifetz AS. Varicella zoster virus infection in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2392-2403
9. Ma C, Walters B, Fedorak RN. Varicella zoster meningitis complicating combined anti-tumor necrosis factor and corticosteroid therapy in Crohn's disease. World J Gastroenterol. 2013;19:3347-3351
10. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009;301:737-744
11. Ito M, Nakano T, Kamiya T, et al. Effects of tumor necrosis factor alpha on replication of varicella-zoster virus. Antiviral Res. 1991;15:183-192
12. Javed S, Kamili QU, Mendoza N, et al. Possible association of lower rate of postherpetic neuralgia in patients on anti-tumor necrosis factor-alpha. J Med Virol. 2011;83:2051-2055
13. Rahier JF, Moreels T, Peeters H, et al. Impact of immunosuppressant and anti-tnf treatment on common infections in IBD patients. Gut. 2012;61 (suppl 3):A46
14. Colombel JF, Sandborn WJ, Panaccione R, et al. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm Bowel Dis. 2009;15:1308-1319
15. Lichtenstein GR, Rutgeerts P, Sandborn WJ, et al. A pooled analysis of infections, malignancy, and mortality in infliximab-and immunomodulatortreated adult patients with inflammatory bowel disease. Am J Gastroenterol. 2012;107:1051-1063
16. Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med. 2012;367:1519-1528
17. Sandborn W, Gasink C, Blank M, et al. O-001 a multicenter, doubleblind, placebo-controlled phase3 study of ustekinumab, a human IL-12/ 23P40 mAB, in moderate-service Crohn's disease refractory to anti-TFNalpha: UNITI-1. Inflamm Bowel Dis. 2016;22(suppl 1):S1
18. Shalom G, Zisman D, Bitterman H, et al. Systemic therapy for psoriasis and the risk of herpes zoster: a 500,000 person-year study. JAMA Dermatol. 2015;151:533-538
19. Failla V, Nikkels AF. Ustekinumab and herpes zoster. Dermatology. 2011;222:119-122
20. Umezawa Y, Fukuchi O, Ito T, et al. Risk of herpes zoster in psoriatic patients undergoing biologic treatment. J Dermatol. 2014;41:168-170
21. Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012; 367:616-624
22. Winthrop KL, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014; 66:2675-2684
23. Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8:443-468
24. Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short-and long-term toxicity. Ann Intern Med. 1989;111:641-649
25. Korelitz BI, Fuller SR, Warman JI, et al. Shingles during the course of treatment with 6-mercaptopurine for inflammatory bowel disease. Am J Gastroenterol. 1999;94:424-426
26. Shale MJ, Seow CH, Coffin CS, et al. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther. 2010;31:20-34
27. Wendling D, Streit G, Toussirot E, et al. Herpes zoster in patients taking TNFalpha antagonists for chronic inflammatory joint disease. Joint Bone Spine. 2008;75:540-543
28. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352: 2271-2284
29. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57:1-30; quiz CE2-4
30. Morrison VA, Oxman MN, Levin MJ, et al. Safety of zoster vaccine in elderly adults following documented herpes zoster. J Infect Dis. 2013;208: 559-563
31. Van Epps P, Schmader KE, Canaday DH. Herpes zoster vaccination: controversies and common clinical questions. Gerontology. 2016;62: 150-154
32. Schmader KE, Levin MJ, Gnann JW Jr, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012;54:922-928
33. Schmader KE, Oxman MN, Levin MJ, et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis. 2012;55:1320-1328
34. Morrison VA, Johnson GR, Schmader KE, et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis. 2015;60:900-909
35. Hales CM, Harpaz R, Ortega-Sanchez I, et al. Update on recommendations for use of herpes zoster vaccine. MMWR Morb Mortal Wkly Rep. 2014;63:729-731
36. Mullane KM, Winston DJ, Wertheim MS, et al. Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults. J Infect Dis. 2013;208:1375-1385
37. Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087-2096
38. Berkowitz EM, Moyle G, Stellbrink HJ, et al. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis. 2015;211:1279-1287
39. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68:1-26
40. Malhi G, Rumman A, Thanabalan R, et al. Vaccination in inflammatory bowel disease patients: attitudes, knowledge, and uptake. J Crohns Colitis. 2015;9:439-444
41. Yun H, Xie F, Delzell E, et al. Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. Arthritis Care Res (Hoboken). 2015;67:731-736
42. Cheetham TC, Marcy SM, Tseng HF, et al. Risk of herpes zoster and disseminated varicella zoster in patients taking immunosuppressant drugs at the time of zoster vaccination. Mayo Clin Proc. 2015;90:865-873
43. Zhang J, Delzell E, Xie F, et al. The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. Arthritis Res Ther. 2011;13:R174
44. Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012;308:43-49
45. Naidus E, Damon L, Schwartz BS, et al. Experience with use of Zostavax ((R)) in patients with hematologic malignancy and hematopoietic cell transplant recipients. Am J Hematol. 2012;87:123-125
46. Scheinberg M, Guedes-Barbosa LS, Mangueira C, et al. Yellow fever revaccination during infliximab therapy. Arthritis Care Res (Hoboken). 2010; 62:896-898
47. Available at: www.bhiva.org/documents/Guidelines/Vaccination/2015-Vaccination-Guidelines.pdf. Accessed February 05, 2016
48. Available at: http://www.phac-aspc.gc.ca/publicat/cig-gci/p04-herp-zona-eng. php#ru. Accessed December 01, 2015
49. Available at: http://publications.msss.gouv.qc.ca/acrobat/f/documentation/ piq/chap10-2-4.pdf [in French]. Accessed December 01, 2015